Edward L Snyder
Overview
Explore the profile of Edward L Snyder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yurtsever N, Snyder E
Transfusion
. 2025 Feb;
PMID: 39907501
Background: Misoprostol, a synthetic prostaglandin E1 analogue, is widely used in obstetrics for its uterotonic properties. It is known to cause thermogenic side effects, a fact well-recognized in obstetrics but...
2.
Gehrie E, Young P, Basavaraju S, Bracey A, Cap A, Culler L, et al.
Transfusion
. 2024 Aug;
64(10):2001-2013.
PMID: 39133194
No abstract available.
3.
Wheeler A, Snyder E, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Blood Adv
. 2024 Mar;
8(9):2290-2299.
PMID: 38447116
Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do...
4.
Snyder E, Sekela M, Welsby I, Toyoda Y, Alsammak M, Sodha N, et al.
Trials
. 2023 Dec;
24(1):799.
PMID: 38082326
Background: Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from...
5.
Kerantzas C, Merwede J, Snyder E, Hendrickson J, Tormey C, Kazmierczak B, et al.
Transfusion
. 2022 Sep;
62(12):2458-2463.
PMID: 36178430
Background: In 2019 the Centers for Disease Control and Prevention (CDC) reported a series of 4 transfusion reactions that resulted from contamination of apheresis platelet products. Products involved in all...
6.
7.
Snyder E, Wheeler A, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Transfusion
. 2022 Jun;
62(7):1365-1376.
PMID: 35748490
Background: Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and...
8.
Bruhn R, Karafin M, Hilton J, Kaidarova Z, Spencer B, Qu L, et al.
Qual Life Res
. 2020 May;
29(10):2737-2744.
PMID: 32382935
Purpose: Outpatients with hematologic disease often receive red cell transfusion to treat anemia and fatigue. The effect of transfusion on fatigue-related quality of life and how well this effect is...
9.
Bahar B, Schulz W, Gokhale A, Spencer B, Gehrie E, Snyder E
Br J Haematol
. 2019 Oct;
188(3):465-472.
PMID: 31566724
Pathogen-reduced (PR) platelets are routinely used in many countries. Some studies reported changes in platelet and red blood cell (RBC) transfusion requirements in patients who received PR platelets when compared...
10.
Gehrie E, Snyder E
Hematol Oncol Clin North Am
. 2019 Aug;
33(5):xiii-xiv.
PMID: 31466613
No abstract available.